BioAtla Announces Share Consolidation

Rhea-AI Summary

BioAtla (NASDAQ: BCAB) will effect a 50-for-1 share consolidation effective April 6, 2026 at 12:01 a.m. ET, with trading on a split-adjusted basis expected at market open on April 6, 2026. The move aims to regain compliance with Nasdaq's $1.00 minimum bid requirement.

No fractional shares will be issued; holders entitled to fractions will receive cash based on the closing price at the Effective Time. Equity awards, option exercise prices and plan share pools will be proportionately adjusted. New CUSIP: 09077B203.

Positive

• Share price expected to increase post 50-for-1 consolidation
• Proportional adjustment of options and plan shares preserves equity values
• New CUSIP assigned: 09077B203

Negative

• Share consolidation may reduce share liquidity and float
• Proportional share reductions could affect perceived share counts and investor behavior

Key Figures

Share consolidation ratio: 50-for-1 Effective date: April 6, 2026 Nasdaq bid requirement: $1.00 minimum bid +5 more

8 metrics

Share consolidation ratio 50-for-1 Every fifty shares of common stock converted into one share at effective time

Effective date April 6, 2026 Share consolidation effective at 12:01 a.m. Eastern Time

Nasdaq bid requirement $1.00 minimum bid Share consolidation intended to help regain Nasdaq Capital Market compliance

Pre-merger exchange 50 shares into 1 Merger Agreement converts every fifty shares into one share of surviving corporation

Shelf registration size $200,000,000 Maximum amount of securities under Form S-3 shelf filed January 16, 2026

Unsold prior shelf $195.95 million Unsold securities carried forward into new S-3 shelf under Rule 415(a)(6)

Pre-paid/SEPA capacity $18.75 million Common stock potentially issuable to YA II PN and Anson funds under agreements

Public float $74.4 million Approximate public float as of mid-January 2026 limiting S-3 sales to one-third cap

Market Reality Check

Price: $0.1634 Vol: Volume 577,531 is at 0.45...

low vol

$0.1634 Last Close

Volume Volume 577,531 is at 0.45x the 20-day average, indicating muted pre-news trading interest. low

Technical Shares at $0.1579 are trading below the $0.49 200-day moving average and far under the $1.43 52-week high.

Peers on Argus

Sector peers showed mixed moves (e.g., PSTV -5.98%, TPST -10.06%, IPSC +2.01%), ...

1 Up

Sector peers showed mixed moves (e.g., PSTV -5.98%, TPST -10.06%, IPSC +2.01%), and momentum scanners only flagged a single peer, suggesting this share consolidation announcement is company-specific rather than a broad biotech move.

Common Catalyst Another peer, Plus Therapeutics (PSTV), also announced a reverse stock split today, indicating listing-compliance actions at multiple small-cap biotechs rather than a pure price-driven sector rotation.

Historical Context

5 past events · Latest: Mar 02 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 02	Strategic review, cuts	Negative	-17.5%	Strategic options review with about 70% workforce reduction to cut expenses.
Dec 31	$40M SPV financing	Positive	-20.8%	$40M SPV to fund Oz-V Phase 3 registrational trial in 2L+ OPSCC.
Nov 21	Flexible financing deals	Positive	-25.1%	Up to $22.5M in flexible financing via Pre-paid Advances and equity facility.
Nov 13	Q3 results, pipeline	Positive	+19.8%	Q3 2025 results plus FDA alignment and positive Oz-V and Mec-V updates.
Nov 07	Mec-V OS data	Positive	+7.2%	Mec-V showed 21.5-month median OS in refractory soft tissue sarcoma subtypes.

Pattern Detected

Recent history shows positive clinical and financing news often met with selling, while clinical updates and earnings have occasionally produced strong upside moves, indicating inconsistent but sometimes contrarian reactions to news.

Recent Company History

Over the past six months, BioAtla has combined clinical progress with increasingly financial and strategic moves. In Nov 2025, positive Mec-V survival data and Q3 results with FDA alignment generated gains of 7.23% and 19.75%. However, flexible financing of up to $22.5M, a $40M SPV for Oz-V, and a March 2026 strategic-review with a 70% workforce reduction each saw double-digit declines. Today’s share consolidation fits into this pattern of balance-sheet and listing-focused actions following value-maximization efforts.

Regulatory & Risk Context

Active S-3 Shelf · $200,000,000

Shelf Active

Active S-3 Shelf Registration 2026-01-16

$200,000,000 registered capacity

BioAtla filed a Form S-3 shelf on 2026-01-16 to offer up to $200,000,000 in securities, carrying forward $195.95 million of unsold capacity and including up to $18.75 million in common stock for YA II PN, Ltd. and Anson funds. As of mid-January 2026, public float was about $74.4 million, so potential sales are subject to the one‑third cap under Form S-3 General Instruction I.B.6. The shelf has already seen multiple 424B2 usages in March 2026.

Market Pulse Summary

This announcement implements a 50-for-1 share consolidation effective April 6, 2026, aimed at liftin...

Analysis

This announcement implements a 50-for-1 share consolidation effective April 6, 2026, aimed at lifting the share price above Nasdaq’s $1.00 minimum bid for continued listing. It follows recent strategic reviews, financings, and a new Form S-3 shelf for up to $200,000,000 of securities. Investors may focus on how the reduced share count, ongoing capital-raising tools, and prior double-digit reactions to financing news shape future trading around upcoming clinical and strategic milestones.

Key Terms

share consolidation, cusip, treasury stock, equity incentive plan, +4 more

8 terms

share consolidation financial

"announced that it will effect a 50-for-1 share consolidation"

Share consolidation is a process where a company reduces the total number of its shares by combining multiple existing shares into a smaller number of higher-value shares. This can make each share more expensive and potentially improve the company’s image. For investors, it often means their ownership remains the same, but the value of each share increases, which can influence how the stock is perceived and traded.

cusip financial

"Following the Share Consolidation, the new CUSIP number for the Common Stock"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

treasury stock financial

"every fifty (50) shares of Common Stock issued and outstanding, or held as treasury stock"

Treasury stock is shares that a company has bought back from the public and kept in its own control rather than retiring them. Think of it like a company holding its own tickets in a drawer: those shares no longer vote or receive dividends while held, but the company can reissue or retire them later; this reduces the number of shares available to outside investors and can boost per‑share earnings and influence ownership and stock price.

equity incentive plan financial

"shares of Common Stock available for issuance under the Company’s equity incentive plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

employee stock purchase plan financial

"available for issuance under the Company’s equity incentive plan and employee stock purchase plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

stock options financial

"exercise prices of and number of shares subject to the Company’s outstanding stock options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

warrants financial

"stock options and warrants will likewise be proportionately adjusted"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

par value financial

"common stock, par value $0.0001 per share (the “Common Stock”)"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

AI-generated analysis. Not financial advice.

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it will effect a 50-for-1 share consolidation (the “Share Consolidation”) of its common stock, par value $0.0001 per share (the “Common Stock”), that is expected to become effective on April 6, 2026 at 12:01 a.m. Eastern Time (the “Effective Date”). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol “BCAB” and is expected to begin trading on a split-adjusted basis when the market opens on April 6, 2026. Following the Share Consolidation, the new CUSIP number for the Common Stock will be 09077B203.

The Share Consolidation is intended to increase the per share trading price of the Common Stock to enable the Company to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

At the Company’s Special Meeting of Stockholders held on March 23, 2026, the Company’s stockholders approved a proposal to approve and adopt the Agreement and Plan of Merger, as amended from time to time, including pursuant to Amendment No. 1 to Agreement and Plan of Merger, which was adopted by the Board of Directors of the Company and executed by the parties to that certain Agreement and Plan of Merger, dated as of January 30, 2026 (the “Merger Agreement”), by and between the Company and its wholly-owned subsidiary, BA Merger Sub, Inc. (“Merger Sub”), pursuant to which (i) Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving, and (ii) every fifty (50) shares of Common Stock issued and outstanding, or held as treasury stock, will be converted into one (1) share of common stock of the surviving corporation, which shall be the Company.

On the Effective Date, every fifty (50) shares of the Common Stock issued and outstanding will be automatically converted into one (1) share share of Common Stock. No fractional shares will be issued in connection with the Share Consolidation. Stockholders of record who otherwise would be entitled to receive fractional shares will be entitled to an amount in cash (without interest or deduction) equal to the fraction of one share to which such stockholder would otherwise be entitled multiplied by the closing price of the Common Stock on The Nasdaq Capital Market on the date on which the Effective Time (as defined in the Merger Agreement) occurs.

As a result of the Share Consolidation, the number of shares of Common Stock available for issuance under the Company’s equity incentive plan and employee stock purchase plan will be proportionately reduced. In addition, the exercise prices of and number of shares subject to the Company’s outstanding stock options and warrants will likewise be proportionately adjusted in accordance with their respective terms. The Share Consolidation will not change the par value of the Common Stock nor the authorized number of shares of Common Stock or preferred stock.

Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-Share Consolidation shares. Stockholders owning shares through a bank, broker or other nominee will have their positions automatically adjusted to reflect the Share Consolidation, subject to brokers’ particular processes, and will not be required to take any action in connection with the Share Consolidation.

About BioAtla^®, Inc. 
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has a robust pipeline consisting of ADCs and T cell engagers (TCEs) that utilize its conditionally active platform technology utilizing pH sensitivity to minimize on-target, off-tumor toxicity. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. To learn more about BioAtla, Inc., visit www.bioatla.com.

Clinical stage pipeline:

• Ozuriftamab vedotin (CAB-ROR2-ADC) - Phase 3 in OPSCC
• Mecbotamab vedotin (CAB-AXL-ADC) - Phase 2 in Sarcoma (soft tissue and bone) and mKRAS NSCLC
• Evalstotug (CAB-CTLA-4) - Phase 2 in Unresectable and/or Metastatic Cutaneous Melanoma
• BA3182 – (dual CAB-EpCAM x CAB-CD3 T cell engager) - Phase 1 in adenocarcinoma - BioAtla will continue to conduct the Phase 1 clinical study.

Pre-clinical stage pipeline:

• BA3361 – (CAB-Nectin4-ADC) - data in breast cancer (BT474, T47D), lung cancer (NCI-H322), bladder cancer (HT1376) and pancreatic cancer models; IND-approved.
• BA3151 – (CAB-B7H4-ADC) - data in breast cancer (MX-1) models. 
• BA3142 – (dual CAB-B7H3 x CAB-CD3 TCE) – IND ready; data in melanoma (A375) and pharyngeal cancer (Detroit 562) models.
• BA3311 – (EGFR x CAB-CD3 TCE) – data in lung cancer (A549, HCC827), breast cancer (BT474), and colon cancer (HCT116) models.
• BA3241 – (dual CAB-Trop2 x CAB-CD3 TCE) – data in epidermoid cancer (A431)
  

Partnered Program:

• BA3362 – (dual CAB-Nectin4 x CAB-CD3 TCE) – out-licensed to Context Therapeutics for up to $133.5 Million plus royalties.
  

About BA3182 (CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager Antibody)
BioAtla is developing BA3182 as a potential anticancer therapy for patients with advanced adenocarcinoma. BA3182 is a (CAB) EpCAM x (CAB) CD3 bispecific T cell engager antibody with binding sites for EpCAM and CD3ε designed to bind their respective targets specifically and reversibly under the conditions found in the tumor microenvironment (TME) and to have reduced binding outside of the TME. The CAB selective binding to both the CAB EpCAM and CAB CD3ε arms are required to activate the T cell engagement against the tumor, thus enabling the combined selectivity of each CAB binding arm in the bispecific antibody. BioAtla continues to conduct the ongoing Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of BA3182 in advanced adenocarcinoma patients.

About Ozuriftamab Vedotin (Oz-V)
Oz-V, CAB-ROR2-ADC, is a conditionally and reversibly active antibody drug conjugate directed against ROR2, a transmembrane receptor tyrosine kinase that is present across many different solid tumors including head and neck, lung, cervical, triple-negative breast cancer, and melanoma. Overexpression of ROR2, a non-canonical wnt5A signaling receptor, forms a cancer axis that is associated with poor prognosis and resistance to chemo- and immunotherapies. This Phase 3 stage clinical asset is targeting the treatment of OPSCC patients who have previously progressed on PD-1/L1 therapies with or without platinum chemotherapy. HPV associated expression of E6 and/or E7 oncoproteins drives cancer progression by upregulating ROR2 expression. As such, there is potential to expand the application of Oz-V more broadly beyond OPSCC to all HPV+ cancers, which represents a market opportunity of over $7 billion worldwide. The FDA granted Fast Track Designation to Oz-V for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

About OPSCC
OPSCC is a subset of squamous cell carcinoma of the head and neck (SCCHN) arising from the squamous cells that line the oropharynx, the middle part of the throat. This anatomic region is located behind the oral cavity and OPSCC typically involves tonsils, soft palate, pharyngeal walls, and/or the base of the tongue. A striking year-to-year increase in OPSCC is due to the rapidly increasing incidence of HPV infections which currently represents approximately 80% of OPSCC in the United States. The prognosis is currently poor for patients with recurrent/metastatic OPSCC who have previously received standard treatments including surgery, radiation, platinum-based chemotherapy, and PD-1 inhibitor therapy.

About Mecbotamab Vedotin (Mec-V)
Mecbotamab vedotin (Mec-V), CAB AXL-ADC, is a conditionally and reversibly active antibody drug conjugate targeting the receptor tyrosine kinase AXL. This Phase 2 stage clinical asset is targeting multiple solid tumor indications, including the treatment of mKRAS NSCLC and soft tissue sarcoma.

About Evalstotug
Evalstotug, is a CAB anti-CTLA-4 antibody that is anticipated to enable safer anti-CTLA-4 antibody combination therapies, such as with anti-PD-1 antibody checkpoint inhibitors. Like our other CAB candidates, this Phase 2 clinical asset is designed to be conditionally and reversibly active in the TME. Evalstotug is being developed as a potential therapeutic for multiple solid tumor indications that are known to be responsive to CTLA-4 treatment in combination with a PD-1 blocking agent.

Forward-looking Statements

Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words. Examples of forward-looking statements include, among others, statements we make regarding the timing of effecting the Merger and statements regarding the Company’s ability to regain compliance with all applicable criteria for continued listing on The Nasdaq Capital Market. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: factors that raise substantial doubt about our ability to continue as a going concern and that we will need additional funding to continue development of our CAB technology platform and our CAB product candidates; the risk that the Share Consolidation will not have the intended effects; whether the Company will be able to pursue a strategic transaction, or whether any transaction, if pursued, will be completed on attractive terms or at all; the risk that preliminary or interim clinical results may not be indicative of results from later cohorts or larger populations; potential delays in clinical and preclinical trials; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, or regulatory approval dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; whether regulatory authorities will be satisfied with the design of and results from the clinical studies or take favorable regulatory actions based on results from the clinical studies; our dependence on the success of our CAB technology platform; our ability to enroll patients in our ongoing and future clinical trials; the successful selection and prioritization of assets to focus development on selected product candidates and indications; our ability to form collaborations and partnerships with third parties and the success of such collaborations and partnerships; our reliance on third parties for the manufacture and supply of our product candidates for clinical trials; our reliance on third parties to conduct our clinical trials and some aspects of our research and preclinical testing; potential adverse impacts due to geopolitical or macroeconomic events outside of our control, including health epidemics or pandemics; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2026 and our subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and BioAtla undertakes no duty to update such information except as required under applicable laws.

External Contact: 
Joyce Allaire
LifeSci Advisors, LLC 
jallaire@lifesciadvisors.com

FAQ

What exactly is BioAtla's 50-for-1 share consolidation for BCAB and when does it take effect?

The consolidation converts every fifty (50) BCAB shares into one (1) share, effective April 6, 2026 at 12:01 a.m. ET. According to the company, trading is expected to reflect the split-adjusted share count when markets open on April 6, 2026.

Will BCAB shareholders receive fractional shares after the April 6, 2026 consolidation?

No fractional shares will be issued; affected holders will receive cash for fractions based on closing price. According to the company, cash payments equal the fractional share times the closing Nasdaq price at the Effective Time.

How will the BCAB share consolidation affect stock options, warrants, and employee plans?

Options, warrants, and plan share counts and exercise prices will be proportionately adjusted by 50-for-1. According to the company, these adjustments follow the instruments' terms to preserve economic value for holders.

Why is BioAtla (BCAB) doing the share consolidation on April 6, 2026?

The consolidation aims to raise the per-share trading price to regain compliance with Nasdaq's $1.00 minimum bid requirement. According to the company, the action is intended to satisfy continued listing standards on The Nasdaq Capital Market.

Will BCAB shareholders need to take any action to receive post-consolidation shares?

No action is required for holders of book-entry shares or those through brokers; positions will be automatically adjusted. According to the company, brokers' processes may vary but no shareholder steps are generally needed.

What is the new CUSIP for BioAtla common stock after the consolidation?

The new CUSIP for BioAtla common stock after the 50-for-1 consolidation will be 09077B203. According to the company, this CUSIP becomes effective on the consolidation Effective Date, April 6, 2026.